Why Is Option Care Health (OPCH) Stock Up +32.91% Today?
Key Takeaways
- OPCH shares jumped roughly 32.9% to about $31.06, from a prior close of $23.37.
- The primary catalyst is a definitive agreement for private equity firm Clayton, Dubilier & Rice (CD&R) and McKesson to acquire Option Care Health for $32.05 per share, or roughly $5.8 billion in enterprise value.
- The agreed price represents a premium of approximately 37% to the October 5 closing price.
- CD&R will hold about 51% and McKesson about 49%, with a framework for McKesson to later acquire CD&R's stake.
- Secondary support came from analyst commentary, including Truist reiterating a Buy rating.
- Traders are now watching the gap between the current price and the $32.05 deal price, plus regulatory and shareholder approvals ahead of an expected first-half 2027 close.
Opening Summary
Option Care Health, Inc. (OPCH), the largest independent provider of home and alternate-site infusion services in the United States, staged a powerful rally on Tuesday. Shares climbed about 32.9% to trade near $31.06, up from a prior closing price of $23.37. The move followed the announcement that CD&R and McKesson (MCK) had signed a definitive agreement to acquire the company, taking it private at $32.05 per share.
The Definitive Acquisition Agreement
The decisive driver behind the surge was a confirmed buyout. Under the terms, CD&R and McKesson will acquire OPCH for $32.05 per share in cash, valuing the company at approximately $5.8 billion including debt. The agreed price reflects a premium of roughly 37% over the October 5 closing price, explaining the sharp repricing of the stock toward the deal value.
At closing, CD&R is expected to hold a majority interest of about 51%, while McKesson will invest roughly $1.4 billion for a minority stake of about 49%. The agreement also establishes a framework for McKesson to acquire CD&R's interest in the future, subject to specified conditions and regulatory approvals. Option Care Health is expected to remain a separate company led by its existing management team.
Strategic Rationale and Sector Context
The transaction underscores growing strategic interest in home and community-based infusion care, a segment benefiting from an aging population and the shift of care toward lower-cost, patient-preferred settings. McKesson framed the investment as aligned with its long-term strategy to expand access and affordability for specialty and complex therapies across the care continuum. The deal is also the latest in a series of private equity acquisitions targeting home health services providers, reinforcing investor appetite for the sector.
Analyst Reaction
Analyst commentary provided secondary support. Truist Securities reiterated a Buy rating, citing Option Care Health's strong payer relationships, including in-network status with the top ten plans and coverage of roughly 96% of insured lives, as well as the company's free-cash-flow generation. The firm pointed to the platform's strategic positioning amid durable demand drivers in infusion and alternate-site care.
Market Context and Trading Activity
Trading volume was heavily elevated relative to typical sessions as investors repriced OPCH toward the announced deal value. The rally was company-specific rather than a broad market event, with the stock's move far outpacing the major indices. Notably, the shares settled somewhat below the $32.05 offer price, reflecting a deal spread that accounts for the time to closing and the customary execution risks associated with a transaction expected to complete in the first half of 2027.
What Comes Next for OPCH
The path ahead for OPCH will be shaped primarily by the mechanics of completing the transaction. Shareholders must approve the deal, and the closing remains subject to required regulatory approvals and other customary conditions. Given the expected first-half 2027 completion timeline, the stock is likely to track developments around regulatory review and any potential changes to deal terms. A termination of the agreement would expose shares to downside toward pre-announcement levels. The company's previously reported second-quarter results beat consensus estimates, with adjusted EPS of $0.45 versus expectations of $0.43 and revenue of $1.44 billion, providing fundamental context amid the acquisition-driven repricing.
Trending AI Robots
For traders seeking a systematic approach to markets like this, Tickeron's Trending AI Robots page offers a curated view of AI-driven trading bots. Tickeron provides hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this section. Bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore automated approaches suited to their objectives. Visit the Trending AI Robots page to discover which strategies are currently leading.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
OPCH's Stochastic Oscillator sits in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +3.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where OPCH advanced for three days, in 177 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 60%.
OPCH may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 152 of 217 cases where OPCH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OPCH as a result. In 67 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 70%.
The Moving Average Convergence Divergence Histogram (MACD) for OPCH turned negative on September 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 33 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
OPCH moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for OPCH crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where OPCH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. OPCH’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.723) is normal, around the industry mean (208.195). P/E Ratio (17.348) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (1.101) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.682) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OPCH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of home and alternate site infusion services.
Industry HospitalNursingManagement
Advertisement